Skip to search formSkip to main contentSkip to account menu

BMS 181339

Known as: BMS-181339 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

TaxoidsTaxol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan
A Phase II study of paclitaxel in patients with primary advanced or metastatic breast cancer was conducted by a cooperative study… 
1997
1997
Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice
Paclitaxel (BMS‐181339: Taxol) is a promising agent against previously treated breast cancer. The antitumor activity of… 
1996
1996
[Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
A phase II study of Paclitaxel in patients with ovarian cancer by 3-hour intravenous infusion was undertaken by a cooperative… 
Review
1996
Review
1996
[Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group].
We conducted a multi-institutional (11 facilities), early phase II study of BMS-181339 (paclitaxel), a novel anti-cancer drug… 
1995
1995
Elution of plasticizer (CEHP) from administration set by BMS-181339 ( Pakuritaxel injection ).
1995
1995
BMS-181339 (パクリタキセル注射液) による輸液セットからの可塑剤 (DEHP) の溶出
1994
1994
[A phase II study of BMS-181339 in patients with ovarian cancer. BMS-181339 Ovarian Cancer Study Group].
We conducted a multicenter Phase II study of BMS-181339 in patients with ovarian cancer. The facilities participating were 23 in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)